Posts tagged 'M&A'

The M&A pickup

For those who have a life are less interested in messy details, the explanation for the dealmaking optimism of recent months goes something like this:

– Since roughly last summer (OMT), tail risks are perceived to be down. And despite Washington’s reverse midas touch, the private sector has shown signs of staying resilient, including a streak of a spookily consistent employment reports. Read more

Is someone circling Pacific Drilling?

Does US-listed Pacific Drilling look like a credible takeover target? We think it probably does, 0n balance, and we’d very much like to find out more. Read more

Has FQM’s board approved a £3bn bid? Dunno — UPDATE

It’s 2:45am in Vancouver. Do you know where your investor relations department is?

Here’s this morning’s Daily MailRead more

The growth of M&A litigation

You know the script here. X company announces that it is acquiring Y; a few days later news of a class action law suit ticks across the wires, typically alleging the directors have failed in their fiduciary duties in some manner; thereafter, silence…

Research by Robert Daines and Olga Koumrian at Cornerstone suggests that such litigation has become the norm since the onset of the financial crisis. Read more

Veolia, Suez and the dirty business of denials

Big news in RAW sewage this Saturday evening.

PARIS | Sat Oct 20, 2012 8:33pm BST (Reuters) – Veolia Environnement and Suez Environnement said on Saturday they were not working on a merger after Le Monde newspaper reported the two companies had held talks that fell apart over antitrust concerns. Read more

Breaking: inevitable happens

The exact time of death can be recorded as 1:01pm BST. But, really, the pulse was lost long ago.

BAE Systems and EADS announced that they have decided to terminate their discussions. So should we blame another breakdown in eurozone relations? Or maybe, just maybe, BEADS wasn’t a merger worth saving. Read more

AstraZeneca and Forest Labs: a match made in sellside heaven

Pascal Soriot doesn’t start as AstraZeneca’s new CEO until Monday, yet everyone seems to know what he should do first: go shopping.

The problems soon to be faced by the former Genentech CEO are well known. AstraZeneca is heading towards the steepest of patent cliffs and has so far failed to find anything in the R&D labs that might cushion its fall. Drugs losing US patent protection by 2015 account for a more than a fifth of its sales, rising to nearly a third of sales by 2019. Recent launches of diabetes and heart disease pills have fallen short and what’s in the late-stage pipeline (arthritis, constipation and gout, since you ask) is considered quite likely to fail. Read more

Pinning the tale on a Monster

It’s been a lively few weeks for Monster Worldwide, the recruitment website.

For a company that’s been for sale since February, that’s quite a move. BofA Merrill Lynch and Stone Key Partners have been courting buyers for the past six months and final-round bids went in this week, according to Dealreporter (subscription required). Read more

Taking Stanchart down under

As fantasy banking M&A goes — this isn’t such an outlandish idea, we reckon.

But see what you think: Read more

M&T and Hudson City’s clean capital

Peter Eavis over at Dealbook notes an underrated aspect of the big M&T/Hudson City regional banking deal — regulatory capital:

To do well in annual Federal Reserve stress tests, M&T Bank may want to increase its Tier 1 common ratio substantially. Read more

Awaiting an African Barrick endgame [update] (update II)

Update (8:20am BST): it seems the usually-reliable sources were mostly reliable in this case, though there remains some uncertainty over whether they can tell one Chinese gold company from another.

Barrick Gold statementRead more

The mechanics of a water pump

Well, that was silly.

United Utilities share price chart Read more

It’s hard being a China short seller

It’s a big, big China leveraged buyout — the biggest ever, in fact. Advertising company Focus Media, which is listed in the US, said it has received a $3.5bn takeover offer from its chief executive who is backed by a number of private equity groups, including Carlyle.

It’s gained attention in part because the offer (in the form of a non-binding proposal letter) of $27 per share is higher than the level the shares closed on the last day before the short seller Muddy Waters published the first of several reports criticising the company. Read more

Alexion targeted for Roche poach?

Remember Friday afternoon RAW?  Well, this is most definitely Friday afternoon RAW. Please read the disclaimer carefully.

 Read more

Goodwill to all men, and Microsoft

Microsoft posted the first quarterly loss, of some $0.06 per share, in the company’s publicly-listed history on Thursday. Its flagged $6.2bn writedown of goodwill on the acquisition of aQuantive got the blame.

(Actual underlying earnings were $0.73 per share, while net cash generation is worth highlighting: $31.6bn) Read more

Bidders said to line up for Arkema

RAW*

 Read more

An email arrives announcing a bid…

[Update: the offer has been withdrawn..."recent publicity around the proposal has made it difficult to proceed".]

… and you’re an established but struggling department store operator (think a rubbish John Lewis) and obvious bid target. You’ve never heard of this bidder, but they insist they’re for real. What do you do? Read more

Linde gets oxygenic with Lincare

Section 15 of Germany’s Securities Trading Act, as divined by the Federal Ministry of Justince, requires publicly listed companies in Germany to release any price sensitive announcement “without delay.”

i.e. In the case of chemicals and gases specialist Linde, that means ‘after five days’ Read more

Glenstrata, the tombstone

Just in case the real trophies never get cast, here are the advisers to the $90 $80 $70 $60 $55(?)bn putative merger between Glencore and Xstrata. Click to enlarge.

First there was the foul-up over competition issues. Unbelievably, Glenstrata had not factored in the likelihood of a referral to the European authorities. Read more

Murdoch to do the splits? Really?

At the age of 81, we’d rather Rupert not attempt this in public. But what should we make of the WSJ’s story on Tuesday that News Corporation, the Murdochs’ parent company, is considering splitting in two?

The usual people claiming to be familiar with the situation say a plan is being considered whereby News Corp’s film and television interests would be carved off, leaving its newspapers, book publishing and education businesses as a separate entity. That would leave 20th century Fox, Fox News and the Fox broadcast network separate from newspapers, such as the Sun and the Times of London, as well as the HarperCollins book publishing business. Read more

About that Invensys statement…

Invensys popped almost 27 per cent on Wednesday on the back of some renewed bid speculation. As Paul noted unusually firm speculation has swirled round Invensys for months now and quite a few fingers have been burned as the company consistently failed to supply any confirmatory statements.

The lastest piece of guess-work came via Bloomberg (now updated): Read more

Will Invensys now grace us with a statement?

Kinda nutty this. For months now unusually firm bid speculation has swirled round Invensys. Accompanying press articles have carried progressively more detail. As recently as May 12 the Sunday Times named Siemens, ABB, Emerson and General Electric as all eyeing the British engineer.

But each time the share price has risen in anticipation of a fully-formed takeover, the lack of a confirmatory statement has burned the speculators. Read more

Peltz bets on Lazard, future of M&A

We found out on Monday that Nelson Peltz’s investment firm Trian has a roughly 5.1 per cent chunk of Lazard.

Peltz doesn’t dominate the headlines like certain other activist investors, preferring to pick his spots and eschewing diversification in Trian’s portfolio. But he’s known for getting involved in his companies and has had some influence on the other two big financial services companies in which Trian has large stakes, State Street and Legg MasonRead more

LME snapped up by Hong Kong Exchanges

A $2.15bn bid for the London Metal Exchange has sealed it for HKex, beating Intercontinental Exchange to end a nine-month bidding war. From the statement:

The board of Hong Kong Exchanges & Clearing Limited (“HKEx”) is pleased to announce that on 15 June 2012, HKEx, HKEx Investment (UK) Limited (“HKEx Investment”) and LME Holdings Limited (“LME Holdings”) entered into a Framework Agreement regarding the terms of a recommended cash offer (the “Offer”) for the entire issued and outstanding ordinary share capital of LME Holdings by HKEx Investment, a direct subsidiary of HKEx International Limited (“HKEx International”) and an indirect wholly-owned subsidiary of HKEx (the “Transaction”). Read more

Stelios flies again (updated)

Sir Stelios Haji-Ioannou, easyJet founder and on-going thorn-in-the-side of the existing board, is developing a new airline — across Africa.

In what promises to be a colourful business combination, he’s joining forces with David Lenigas of Lonrho to launch “Fastjet,” a low cost carrier that is promising to operate across the African continent. Read more

Glenstrata, the scheme doc

Click image for the full, 136-page doc.

 Read more

Meet Mick, the Greedy Miner (updated)

 Read more

M&A flows and the (slippy) FX market

M&A flows and their impact on currencies are an especially hard thing to get a grip on – cause and effect can get quite muddied.

A recent note from UBS analyst Chris Walker took another shot at discovering  how M&A flows influence the FX markets. He argues that while M&A flows do influence FX markets, they do so largely because of expectations and speculation — not because of flows directly related to M&A transactions (UBS’ emphasis): Read more

Autonomy: a postscript

Here’s something odd.

Related links:
Lynch mobbed – FT Alphaville
Revisiting Autonomy’s Iron Mountain deal – FT Alphaville Read more

A small, last minute cash call…

Three Alphavillans are running around Canary Wharf in East London this evening in support of the British Heart Foundation.

Left to right: Lisa Pollack, David Keohane and Masa Serdarevic Read more